Literature DB >> 34709667

Experimental comparison of photon versus particle computed tomography to predict tissue relative stopping powers.

Esther Bär1,2, Lennart Volz3, Charles-Antoine Collins-Fekete1, Stephan Brons4, Armin Runz5, Reinhard Wilhelm Schulte6, Joao Seco3,7.   

Abstract

PURPOSE: Measurements comparing relative stopping power (RSP) accuracy of state-of-the-art systems representing single-energy and dual-energy computed tomography (SECT/DECT) with proton CT (pCT) and helium CT (HeCT) in biological tissue samples.
METHODS: We used 16 porcine and bovine samples of various tissue types and water, covering an RSP range from 0.90 ± 0.06 to 1.78 ± 0.05. Samples were packed and sealed into 3D-printed cylinders ( d = 2  cm, h = 5  cm) and inserted into an in-house designed cylindrical polymethyl methacrylate (PMMA) phantom ( d = 10  cm, h = 10  cm). We scanned the phantom in a commercial SECT and DECT (120 kV; 100  and 140 kV/Sn (tin-filtered)); and acquired pCT and HeCT ( E ∼ 200  MeV/u, 2 ∘ steps, ∼ 6.2 × 10 6 (p)/ ∼ 2.3 × 10 6 (He) particles/projection) with a particle imaging prototype. RSP maps were calculated from SECT/DECT using stoichiometric methods and from pCT/HeCT using the DROP-TVS algorithm. We estimated the average RSP of each tissue per modality in cylindrical volumes of interest and compared it to ground truth RSP taken from peak-detection measurements.
RESULTS: Throughout all samples, we observe the following root-mean-squared RSP prediction errors ± combined uncertainty from reference measurement and imaging: SECT 3.10 ± 2.88%, DECT 0.75 ± 2.80%, pCT 1.19 ± 2.81%, and HeCT 0.78 ± 2.81%. The largest mean errors ± combined uncertainty per modality are SECT 8.22 ± 2.79% in cortical bone, DECT 1.74 ± 2.00% in back fat, pCT 1.80 ± 4.27% in bone marrow, and HeCT 1.37 ± 4.25% in bone marrow. Ring artifacts were observed in both pCT and HeCT reconstructions, imposing a systematic shift to predicted RSPs.
CONCLUSION: Comparing state-of-the-art SECT/DECT technology and a pCT/HeCT prototype, DECT provided the most accurate RSP prediction, closely followed by particle imaging. The novel modalities pCT and HeCT have the potential to further improve on RSP accuracies with work focusing on the origin and correction of ring artifacts. Future work will study accuracy of proton treatment plans using RSP maps from investigated imaging modalities.
© 2021 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.

Entities:  

Keywords:  dual-energy computed tomography; particle computed tomography; proton stopping power

Mesh:

Substances:

Year:  2021        PMID: 34709667     DOI: 10.1002/mp.15283

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  4 in total

1.  The accuracy of helium ion CT based particle therapy range prediction: an experimental study comparing different particle and x-ray CT modalities.

Authors:  L Volz; C-A Collins-Fekete; E Bär; S Brons; C Graeff; R P Johnson; A Runz; C Sarosiek; R W Schulte; J Seco
Journal:  Phys Med Biol       Date:  2021-11-29       Impact factor: 3.609

2.  Potential of a Second-Generation Dual-Layer Spectral CT for Dose Calculation in Particle Therapy Treatment Planning.

Authors:  Friderike K Longarino; Antonia Kowalewski; Thomas Tessonnier; Stewart Mein; Benjamin Ackermann; Jürgen Debus; Andrea Mairani; Wolfram Stiller
Journal:  Front Oncol       Date:  2022-04-20       Impact factor: 5.738

Review 3.  Considerations for Upright Particle Therapy Patient Positioning and Associated Image Guidance.

Authors:  Lennart Volz; Yinxiangzi Sheng; Marco Durante; Christian Graeff
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

4.  Assessment of quantitative information for radiation therapy at a first-generation clinical photon-counting computed tomography scanner.

Authors:  Guyue Hu; Katharina Niepel; Franka Risch; Christopher Kurz; Matthias Würl; Thomas Kröncke; Florian Schwarz; Katia Parodi; Guillaume Landry
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.